BDBM246231 US10183932, Example 138::US9434690, 136::US9434690, 137::US9434690, 138::US9822102, Example 138

SMILES COc1cn(C(CCOC(F)(F)F)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1C#N

InChI Key InChIKey=YNXCWDXRPDZZLO-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 246231   

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.60nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.60nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 6.5nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 6.5nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 6.5nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 9.40nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 9.40nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 9.40nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.20E+3nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.20E+3nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246231(US9434690, 136 | US9434690, 138 | US9434690, 137 |...)
Affinity DataIC50: 1.20E+3nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
US Patent